[Do dendritic cells modified with retroviral vectors carrying cytokine genes become a therapeutic tool?].
For many years, the application of various types of immunostimulators (among which cytokines have proved to play a crucial role) has been one of the ways to enhance anti-tumor immunity. Dendritic cells genetically modified towards cytokine production have been proposed as a potential therapeutic tool to enable restoration of the cytokine environment diminished by a growing tumor. Retroviral vectors have been the most often used carriers of cytokine genes. Therefore, optimization of the genetic procedure of inserting retroviral vectors into DCs has been widely studied largely in order to achieve better immunotherapeutic effects against tumor.